Guardion Health Sciences (GHSI) Reports Clinical Results Indicating that Viactiv Omega Boost Gel Bites Increase Omega-3 Levels in Just 4 weeks

Guardion Health Sciences, Inc. (Nasdaq: GHSI), a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professions and providers and their patients, announces interim four-week results of a clinical study designed to evaluate the effectiveness of new Viactiv Omega Boost Gel Bites at increasing Omega-3 saturation levels on red blood cells. The 1,200 mg Omega-3 gel bites contain both DHA and EPA and are designed to provide total body support, including cardiovascular, brain, immune and eye health.

The new gel bite dosage form provides the potency of large, hard-to-swallow soft gels, in a great tasting chewable format that has more than ten times the amount of Omega-3s than the leading omega-3 gummy. The gel bite delivery has no sugar and no unpleasant fishy aftertaste.

“Our interim clinical results showed a 51% improvement in Omega-3 levels in just 4 weeks which exceeded our expectations,” commented Bret Scholtes, Guardion’s Chief Executive Officer. “Although Viactiv Omega Boost is positioned at a more premium price point, it is a better value for our consumers because it is proven to work. The amount of high-quality Omega-3s in a supplement does matter, and this product reflects Guardion’s continuing commitment to deliver science-based, clinically supported product that can make a difference in the health of our customers.”

Viactiv Omega Boost™ is available for sale at www.viactiv.com

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• BeiGene (BGNE) Receives EU Approval for Tislelizumab